Super Micro Computer Reports Disappointing Q1 Results, Alongside Pinterest, Axon Enterprise, and Other Major Stocks Declining in Wednesday's Pre-Market Trading
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Updated: Nov 05 20250mins
U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures dropping over 50 points, reflecting a negative market sentiment.
Super Micro Computer Performance: Super Micro Computer Inc. shares fell 9.2% after reporting disappointing first-quarter earnings of 35 cents per share, missing estimates, and issuing lower second-quarter EPS guidance.
Other Notable Stock Declines: Several companies, including Biohaven Ltd and Trex Company Inc, experienced significant pre-market declines, with Biohaven tumbling 46.2% after receiving an FDA Complete Response Letter.
Mixed Results from Major Firms: Companies like Axon Enterprise and Pinterest reported mixed third-quarter results, leading to notable drops in their stock prices, with Axon down 19.6% and Pinterest down 18.8%.
BHVN.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 16.82 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 9.610
Low
9.00
Averages
16.82
High
30.00
Current: 9.610
Low
9.00
Averages
16.82
High
30.00
H.C. Wainwright
H.C. Wainwright
Buy
to
Neutral
downgrade
$30 -> $11
2025-12-03
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $11
2025-12-03
New
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright downgraded Biohaven to Neutral from Buy with a price target of $11, down from $30. The company reduced operating expenses and raised additional funding, "but now needs clear wins to keep the pipeline moving," the analyst tells investors in a research note. The firm sees a low likelihood that opakalim's Phase 3 data will exceed, or even match, azetukalner's efficacy. It downgrades the shares seeing "fewer ways to win."
UBS
Buy -> Neutral
downgrade
$26 -> $11
2025-11-26
Reason
UBS
Price Target
$26 -> $11
2025-11-26
downgrade
Buy -> Neutral
Reason
UBS downgraded Biohaven to Neutral from Buy with a price target of $11, down from $26. The firm says the company's "multiple" research and development and regulatory setbacks have lowered confidence on the viability of its remaining pipeline programs. Most of the immediate value in Biohaven's pipeline comes from Kv7, but the company is two years behind competitor Xenon in the primary indication, the analyst tells investors in a research note. UBS sees a balanced risk/reward for the shares into the upcoming pipeline catalysts.
JPMorgan
Overweight -> NULL
downgrade
$47 -> $15
2025-11-20
Reason
JPMorgan
Price Target
$47 -> $15
2025-11-20
downgrade
Overweight -> NULL
Reason
JPMorgan lowered the firm's price target on Biohaven to $15 from $47 and keeps an Overweight rating on the shares. The firm finds it "prudent" for Biohaven to undertake cost optimization efforts and restructure its business priorities following the complete response letter for Vyglxia. This should help refocus investor attention on the company's key value drivers, the analyst tells investors in a research note.
Morgan Stanley
Overweight
to
NULL
downgrade
$54 -> $26
2025-11-18
Reason
Morgan Stanley
Price Target
$54 -> $26
2025-11-18
downgrade
Overweight
to
NULL
Reason
Morgan Stanley lowered the firm's price target on Biohaven to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA regarding its NDA for Troriluzole in spinocerebellar ataxia, the firm removed Troriluzole and updated its model following Q3 results. The next catalyst for the stock is Opakalim Phase 2 data in major depressive disorder that is expected in Q4, the analyst tells investor
See All Ratings
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did HC Wainwright downgrade Biohaven from Buy to Neutral?
What factors led to the 23.10% reduction in Biohaven's price target?
How will Biohaven's stock price perform in the next quarter?
Will the reduced fund sentiment impact Biohaven's market performance long-term?